The Centers for Medicare & Medicaid Services today announced a new Section 1115 waiver policy that allows states to design demonstration projects that increase access to treatment for opioid use disorders and other substance use disorders. CMS’s new demonstration policy would allow state Medicaid programs to reimburse for substance abuse treatment provided at inpatient facilities with more than 16 beds otherwise prohibited by the current Institutions for Mental Diseases exclusion. While the new policy will provide states with an expedited review process, it does require that states submit a detailed implementation plan that articulates how they will meet the new policy’s specific goals and milestones to improve OUD and SUD treatment and reduce opioid related deaths. In addition to the implementation plan, states also must comply with periodic reporting and evaluations. CMS also announced approval of New Jersey and Utah’s 1115 demonstration waivers under the new policy.

Related News Articles

Headline
The Health Resources and Services Administration yesterday awarded 120 organizations, including hospitals, $200,000 each to develop community partnerships and…
Headline
Laws that allow pharmacists to dispense the opioid antidote naloxone without a physician’s prescription are associated with a sharp reduction in fatal opioid-…
Headline
The White House Office of National Drug Control Policy seeks by 2022 to reduce drug overdose deaths and youth illicit drug use by 15 percent and opioid…
Perspective
Investing in our country’s health infrastructure is the right move to make.
Headline
The AHA yesterday announced support for the Opioid Workforce Act of 2019, bipartisan legislation to reduce the nation’s shortage of opioid treatment providers…
Headline
The National Academy of Medicine Action Collaborative on Countering the U.S. Opioid Epidemic, of which the AHA is a sponsor, held a two-day meeting this week…